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Edited by Guido TettamantiAbstract The release of cysteine cathepsins from the lysosome
into the cytoplasm can trigger programs of cell death (PCD) that
do not require caspase executioner proteases but instead are
mediated by toxic reactive oxygen species (ROS). Here, we show
that a cytoplasmic inhibitor of papain-like cathepsins – Serine
protease inhibitor 2A (Spi2A) – is required for the protection of
cells from caspase-independent PCD triggered by tumor necrosis
factor-. In the absence of caspase activity, Spi2A suppressed
PCD by inhibiting cathepsin B after it was released into the
cytoplasm. Spi2A also directly protected against ROS-mediated
PCD, which is consistent with a role in suppressing caspase-
independent pathways of PCD. We conclude that inhibition of
lysosomal executioner proteases by Spi2A is a physiological
mechanism by which cells are protected from caspase-indepen-
dent programmed cell death.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Programmed cell death; Cathepsin B; Serine
protease inhibitor 2A; Caspase-independent cell death;
Lysosomal pathway of cell death1. Introduction
Programmed cell death (PCD) is an active process by which
signaling events induce the death of cells [1]. Classical apop-
tosis is the principle program of cell death in many develop-
mental and physiological settings. Recent ﬁndings indicate
that PCD can occur in the complete absence of caspase ac-
tivity [2]. Like classical apoptosis, caspase-independent PCD
can be triggered by death receptors, and results in the depo-
larization of mitochondria, generation of ROS and the release
of apoptogenic factors like cytochrome c and apoptosis-
inducing factor (AIF) [2]. This means that even in the absence
of caspase activity the cell is still subjected to factors that still
provoke PCD.
Lysosomal proteases called cathepsins can trigger the
whole spectrum of morphologically distinct programs of cell
death ranging from coagulative necrosis to classical apoptosis
[3]. Depending on the cell type and the stimuli, cathepsins,
most notably cathepsin B, released from the lysosome into
the cytoplasm may function upstream [4,5] or downstream [6]
of caspases. In tumor cells, following stimulation of tumor
necrosis factor-a (TNF-a) receptor 1 (TNFR1), the release of* Corresponding author. Fax: +1-773-702-1576.
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cytoplasm can occur in the absence of caspase activity
through mechanisms which are not fully understood [6]. It
has been suggested that the potent caspase-independent PCD,
which is unmasked by mutations in caspases [7] or the use of
pharmacological inhibitors such as Z-VAD.fmk [8–10], rep-
resents a back-up mechanism for cell death which may be
especially important in pathological situations. It is believed
that in the absence of caspase activity cathepsins play a
dominant role as executioner proteases acting both upstream
or downstream of toxic ROS generated in the mitochondria
[2].
The program of gene expression induced by RelA/NF-jB
transcription factors is critical to the control of cell survival
[11]. Ligation of TNFR1 not only induces PCD, but also ac-
tivates NF-jB, which counteracts this process by activating the
transcription of genes encoding inhibitors of classical caspase-
dependent apoptosis. However, whether NF-jB can protect
against caspase-independent PCD is not known. We have re-
cently reported that NF-jB protects murine ﬁbroblasts from
the lysosomal pathway of PCD by upregulating the expression
of the mouse gene Serine protease inhibitor 2A (Spi2A) (Ac-
cession number: M64085) [12,13]. Spi2A is an unusual member
of the anti-chymotrypsin family of serine protease inhibitors
(serpins) because it is not secreted and resides in the cytoplasm.
Furthermore, it is a potent inhibitor of papain-like cysteine
proteases such as cathepsin B and L [14]. Induction of Spi2A
expression by NF-jB extinguished cathepsin B activity in the
cytosol and protected cells from classical caspase-dependent
apoptosis [14].
We report that Spi2A was required for the protection of cells
from death caused by the ligation of TNFR1 in the presence of
Z-VAD.fmk. In the absence of caspase activity, protection by
Spi2A was accompanied by the suppression of mitochondrial
depolarization and ROS production. Experiments with the
redox-cycling drug Naphthazarin indicate a direct role for
Spi2A in protecting against cell injury from ROS. Thus, in-
hibition of lysosomal executioner proteases is a cyto-protective
mechanism by which NF-jB can protect against programs
of cell death not dependent on classical caspase-dependent
apoptosis.2. Materials and methods
2.1. TNF-a death assays
NIH3T3 cells were transduced with MIGR1 retrovirus [15] encoding
either GFP alone, or Spi2A in the forward (sense) or reverse (anti-
sense) orientation and stable clones generated, as described previously
[14]. Cells were treated with TNF-a (R&D) and after 16 h the numberblished by Elsevier B.V. All rights reserved.
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[14]. Live cells were deﬁned as those that excluded propidium iodide
(PI-negative) and had the appropriate size, as deﬁned by forward and
side light scatter characteristics. Caspase activity was inhibited by pre-
treatment of cells or extracts for 1 h with Z-VAD.fmk (ICN Bio-
medicals Inc; 50 lM). Complete inhibition of caspase activity was
veriﬁed by enzyme assay [14]. The level of Spi2A mRNA was quanti-
tated by real-time PCR using primers and probes speciﬁc for Spi2A
[12] and cycloﬁlin A control mRNA [16], either before (Fig. 1B) or 4 h
after (Fig. 2A) treatment with Z-VAD.fmk (50 lM) and TNF-a
(10 ngml1), as described previously [14].
2.2. ROS-mediated death assays
NIH3T3 cells were treated with the redox-cycling quinone Naph-
thazarin (5,8-dihydroxyl-1,4-naphthoquinone) (Sigma–Aldrich; 10
lM) and survival measured after 2 h at 37 C, as described before [4].
Protection from ROS-mediated death was aﬀorded by treatment with
the anti-oxidant N ;N 0-diphenyl-p-phenylenediamine (DPPD) (Sigma–
Aldrich; 1–2 lM), 30 min before addition of the quinone [17].
2.3. Death eﬀector assays
Death eﬀector pathways were induced by treatment of NIH3T3
cells with TNF-a (10 pgml1) and Z-VAD.fmk (50 lM). Colori-
metric assays for cathepsin B were performed on crude cytoplasmic
extracts [18]. Brieﬂy, NIH3T3 cells (106) were lysed in 10 mM
Tris Cl, pH 7.5, 100 mM NaCl, 1 mM EDTA, and 0.01% Triton X-
100 (50 ll) for 30 min on ice, then centrifuged at 15 000 g for
30 min at 4 C and the supernatant recovered. Protein concentration
was determined by Lowry assay (DC-protein assay kit, Biorad).
Cathepsin B was assayed in reaction buﬀer using the p-Nitoaniline
(pNA)-labeled substrate Z-RR-pNA (Calbiochem) [19]. Speciﬁc ac-
tivity was determined by subtracting the apparent activity detected in
the presence of the cathepsins B inhibitor, CA074-Me (30 lM) in-
hibitor (Peptide Institute) [14]. Mitochondrial membrane potential
and ROS production was measured using the ﬂuorescent dyes JC-1
(3 lgml1) and Dihydroethidium (HE) (5 lM)(Molecular Probes),
respectively, and ﬂow cytometry according to the manufacturer’s
instructions.3. Results
3.1. Spi2A protects from caspase-independent PCD
Complete inhibition of caspase activity by Z-VAD.fmk can
sensitize normally resistant cells with wild-type levels of NF-
jB to TNF-a-induced PCD [8,9]. In Fig. 1A, as expected [9],Fig. 1. Spi2A protects NIH3T3 cells from caspase-independent death induce
with Z-VAD.fmk (50 lM) alone or TNF-a (10 ngml1) alone or both. The
(100% recovery) to determine the percentage of recovery. Values are means (
three clones of NIH3T3 cells transduced with retrovirus encoding GFP alon
niﬁcant diﬀerences between duplicate determinations on individual clones w
sentatives of two independent experiments. (C) Percentage survival of cells af
incubated with TNF-a at 0.01 ngml1 (10 pgml1) was nominally designated
cells incubated alone. Values are means (S.E.M.) from four wells ðn ¼ 4Þ.we show that complete inhibition of caspase activity by Z-
VAD.fmk sensitized NIH3T3 ﬁbroblasts to PCD by TNF-a.
Lysosomal cathepsins, such as cathepsin B, can induce PCD
in the absence of caspase activity [6]. This raises the possibility
that because Spi2A is a potent inhibitor of cathepsin B, it may
protect against a caspase-independent program of cell death
[20]. To address this, NIH3T3 cells were transduced with ret-
rovirus encoding Spi2A (Spi2A cells) on a polycistronic
mRNA with green ﬂuorescent protein (GFP) and stable clones
which express high levels of Spi2A generated [14,15]. The ex-
pression of Spi2A in transduced clones was veriﬁed by real-
time PCR (Fig. 1B). In the absence of caspase activity Spi2A
cells exhibited markedly improved survival against TNF-a
(0.1–30 ngml1), compared to cloned cells transduced with
GFP alone (GFP cells) (Fig. 1C). Therefore, we conclude that
Spi2A can protect against caspase-independent PCD.
3.2. Spi2A is a physiological inhibitor of caspase-independent
PCD
To verify that cyto-protection from caspase-independent
PCD mediated by Spi2A was not due to overexpression, we
generated clones of NIH3T3 cells expressing Spi2A in an anti-
sense orientation (Spi2A-A cells) [14]. We have shown before
that treatment with TNF-a induces the expression of Spi2A in
an NF-jB-dependent manner [14]. As expected, real-time PCR
revealed that in the presence of Z-VAD.fmk, treatment with
TNF-a resulted in the upregulation of Spi2A mRNA in con-
trol NIH3T3 cells [16] (Fig. 2A). Importantly, after treatment
with TNF-a, the upregulation of endogenous Spi2A mRNA
was abrogated in stable clones of Spi2A-A cells (Fig. 2A).
In the absence of caspase activity, the inhibition of endog-
enous Spi2A mRNA expression by anti-sense message resulted
in a marked increase in the susceptibility of cells to TNF-a-
induced PCD, which was measured over the picomolar range
of concentrations (0.03–10 pgml1; Fig. 2B). Higher concen-
trations of TNF-a (nanomolar range) were required to dem-
onstrate that overexpression of Spi2A decreased sensitivity to
caspase-independent PCD (Fig. 1C). Importantly, in both ex-
periments the survival of the GFP control cells with 10 pgml1d by TNF-a. (A) Percentage survival of NIH3T3 cells after treatment
recovery of cells after 16 h was compared with those incubated alone
S.E.M.) from four wells ðn ¼ 4Þ. (B) Expression of Spi2A mRNA in
e (GFP) or Spi2A (Spi2A cells) as determined by real-time PCR. Sig-
ere determined by student’s t-test ðP < 0:001Þ. The data are repre-
ter treatment with TNF-a+Z-VAD.fmk (50 lM). The recovery of cells
as 100% recovery and for GFP clones this was 70% of the recovery of
Fig. 2. Spi2A is a physiological inhibitor of lysosomal pathway of death in the absence of caspase activity. (A) Endogenous Spi2A mRNA levels
measured by real-time PCR in three clones of NIH3T3 cells transduced by retrovirus encoding GFP alone (GFP clones) or anti-sense Spi2A (Spi2A-
A clones) 4 h after treatment with either Z-VAD.fmk (50 lM) or Z-VAD.fmk+TNF-a (10 ngml1). There was a signiﬁcant diﬀerence in Spi2A
expression ðP < 0:001Þ between GFP and Spi2A-A clones after treatment with VAD.fmk+TNF-a. The data are representatives of two independent
experiments. (B) Percentage survival of three clones of GFP or Spi2A-A NIH3T3 cells after treatment with TNF-a+Z-VAD.fmk (50 lM). The
recovery of cells after 16 h was compared with those incubated with TNF-a at 0.01 pgml1 (100% recovery). Values are the means (S.E.M.) from
four wells ðn ¼ 4Þ. (C) Cathepsin B activity in crude cytoplasmic extracts from three clones of GFP or Spi2A-A NIH3T3 cells before (time¼ 0 h) or
after (time¼ 8 h) treatment with TNF-a+Z-VAD.fmk (50 lM). There was a signiﬁcant diﬀerence in cathepsin B speciﬁc activity between GFP and
Spi2A-A clones ðP < 0:001Þ. The data are representatives of two independent experiments.
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GFP-cells with Z-VAD.fmk alone; legend to Figs. 1 and 2B).
We have shown previously that Spi2A has no direct eﬀect on
NF-jB activation, therefore it is unlikely that the knock-down
in Spi2A expression increased PCD by impairing NF-jB
function [14]. Thus, Spi2A is required to antagonize TNF-a-
induced PCD in the absence of caspase activity.
3.3. Spi2A is a physiological inhibitor of the lysosomal pathway
of death in the absence of caspase activity
Spi2A is located in the cytoplasm and so can protect from
classical caspase-dependent apoptosis by suppressing
cytoplasmic cathepsin B activity after it is released from the
lysosome [14]. We wanted to determine if this mechanism of
cyto-protection by Spi2A extends to the inhibition of caspase-
independent PCD. In the absence of caspase activity, the
inhibition of endogenous Spi2A mRNA expression by anti-
sense Spi2A resulted in the induction of cytoplasmic cathep-
sin B activity after treatment of NIH3T3 cells with TNF-a
(Fig. 2C). Thus, the inhibition of cytosolic cathepsin B by
Spi2A is a physiologically relevant mechanism by which
Spi2A blocks the lysosomal pathway of cell death in the
absence of caspase activity.3.4. Spi2A suppresses mitochondrial pathways of PCD in the
absence of caspase activity
The permeabilization of the outer membrane of the mito-
chondrion is central to most caspase-independent death pro-
grams [2]. One important consequence of damaged
mitochondria is the release of ROS, which are thought to be
particularly important in mediating TNF-a cytotoxicity [21].
Given the ability of Spi2A to protect from caspase-indepen-
dent PCD, we determined whether Spi2A could protect cells
from mitochondrial depolarization and ROS production. The
knock-down in Spi2A expression resulted in the onset of mi-
tochondrial depolarization (Fig. 3A) and ROS production
(Fig. 3B) after treatment of Spi2A-A cells with Z-VAD.fmk
and TNF-a. Therefore, we conclude that Spi2A is a physio-
logical inhibitor of ROS production in the absence of caspase-
activity.
3.5. Spi2A protects from death caused by ROS
A mechanism by which ROS can cause cellular injury is
through the release of digestive cathepsins into the cytoplasm
after damaging lysosomal membranes [4,17]. Therefore, we
determined whether Spi2A can protect cells from death caused
directly by ROS. In Fig. 4A, as expected we show that the
52 N. Liu et al. / FEBS Letters 569 (2004) 49–53redox cycling quinone Naphthazarin induces the PCD of
NIH3T3 cells and that this can be reversed by the addition of
the anti-oxidant DPPD. As has been shown for cathepsin D
[4], we show that oxidative damage induced by Naphthazarin
results in the release of cathepsin B from the lysosome into the
cytoplasm (Fig. 4B). In Fig. 2C and in another study [14], we
show that Spi2A is a physiologically relevant inhibitor of ca-
thepsin B in the cytoplasm. Importantly, the expression of
Spi2A protected cells from PCD caused by Naphthazarin
(Fig. 4C). We conclude that Spi2A can protect from ROS-
mediated PCD, most likely through the suppression of ca-
thepsin B in the cytoplasm.4. Discussion
There is an increasing realization that programs of cell death
that do not require caspases may be of consequence in a va-
riety of physiological settings [2]. Our present study is the ﬁrst
description of an endogenous serpin protecting cells from
caspase-independent PCD. Caspase-independent PCD is an
important component of the TNF-a-induced toxicity. There-
fore, the ﬁnding that the Spi2A gene maps to the ‘‘TNF-pro-
tection locus’’ on mouse chromosome 12 suggests that the0
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Fig. 3. Spi2A inhibits mitochondrial PCD in the absence of caspase activity
were treated with TNF-a (10 pgml1) +Z-VAD.fmk (50 lM), then (A) mitoc
The values are the means of duplicate determinations ðn ¼ 2Þ. The data aresuppression of caspase-independent PCD by Spi2A may be of
wide physiological relevance [22].
We have reported previously that Spi2A can abrogate clas-
sical caspase-dependent apoptosis not by direct inhibition of
caspases, but rather through the inhibition of mitochondrial
damage through suppression of cathepsin B activity in the
cytoplasm [14]. This conclusion was based on the inability of
Spi2A to inhibit caspase 3, 8 or 9 activity in vitro. However, we
could not exclude the possibility that the suppression of PCD
by Spi2A was due not only to the inhibition of lysosomal
cathepsins but also the inhibition of caspases other than the
ones we have tested. In this study, we observed as have others
[8–10] that even when caspase activation was suppressed by Z-
VAD.fmk, TNF-a still triggered the release of cathepsin B
from the lysosomes, induced mitochondrial permeabilization
and induced ROS production. Importantly, the present study
clearly indicates for the ﬁrst time that the abrogation of PCD
by Spi2A does not require caspases as targets of inhibition.
In the absence of caspase-activity the cell is still susceptible
to PCD from a range of factors. For example, AIF and the
pro-apoptotic member of the Bcl-2 family – Bax – can induce
apoptosis by dissipating mitochondrial potential in a Z-
VAD.fmk-insentitive manner [20]. The damage of mitochon-
dria that occurs in the absence of caspase activity leads to the0
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suggested that other proteases, such as calpains, serine prote-
ases and cathepsins substitute as dominant executioner pro-
teases [20]. We show that in the absence of caspase activity
TNFR1-ligation induces mitochondrial depolarization and
ROS production, which damages lysosomes and releases
cathespin B into the cytoplasm. Spi2A is required to protect
against death caused by TNFR1 by inhibiting cytoplasmic
cathepsin B released after lysosomal damage. Therefore, we
propose that this activity of Spi2A mediates protection against
ROS-mediated PCD.
Cyto-protection from PCD that does not require caspase
activity may be aﬀorded by other serpins that inhibit cathep-
sins. For example, the inhibition of cathepsins has been de-
scribed by the human serpins SCCA 1 and 2 and the mouse
serpin SQN-5 [23,24]. Furthermore, overexpression of SCCA2
protected HeLa cells from TNF-a-mediated PCD [25].
Lysosomal cathepsins play a role in both apoptosis and
necrosis [3]. The importance of necrotic cell death in patho-
logical processes in fact predates the discovery of apoptosis
[1,3]. However, more recent ﬁndings indicate that necrotic,
caspase-independent PCD is of physiological relevance in limb
development in mice [26] and cell speciﬁcation in Drosophila
and C. elegans [20]. Studies with in vivo models will hopefully
shed light on the role of Spi2A in both development and
disease.
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